Maintenance Pazopanib in Ovarian Cancer: No Survival Benefi...
Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High Rate of Complications
(Sept. 25, 2014) Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical Oncology. In this clinical trial, which … Continued